Source MS Society
We’re proud to be co-funding the phase 3 trial to test if simvastatin could become a treatment for secondary progressive MS. This phase 3 trial will involve over 1000 people with secondary progressive MS. It began in March 2017 and will take six years to complete.If successful, simvastatin could be among the first treatments licensed for secondary progressive MS.
The phase 3 trial will cost almost £6 million. We’re funding this research in collaboration with the National Institute for Health Research, the National MS Society (US), the NHS and UK universities. Read on.